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Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at 
reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, 
clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, 
we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, 
depicts a similar safety profile and that sequential local inoculation of LTX-401 was able to cure 
immunocompetent host from subcutaneous MCA205 and TC-1 cancers. Cured animals exhibited 
long term immune memory effects that rendered them resistant to rechallenge with syngeneic 
tumors. Nevertheless, the local treatment with LTX-401 alone had only limited abscopal effects on 
secondary contralateral lesions. Anticancer effects resulting from single as well as sequential 
injections of LTX-401 were boosted in combination with PD-1 and CTLA-4 immune checkpoint 
blockade (ICB), and sequential LTX-401 treatment combined with double ICB exhibited strong 





The word ‘oncolysis’ usually evokes oncolytic viruses, i.e. viruses that selectively infect and kill 
cancer cells.1, 2 However, oncolysis can also be achieved by applying physical, chemical or 
pharmacological agents to tumor in a way that the cancer is locally destroyed. For example, cationic 
ampholytic peptides or peptide mimetics can be used to target cellular membranes, causing their 
disruption by detergent-like effects. We have been characterizing the mode of action of several 
oncolytic reagents of this class such as LTX-315, LTX-401, DTT-205 and DTT-304. LTX-315 
turned out to preferentially target mitochondrial membranes;3, 4 while LTX-401 destroys Golgi 
apparatus-associated membranes,5-7 thus setting off a different cell-destroying cascade.7 DTT-205 
and DTT-304, instead, have a tropism for lysosomal membranes, thus activating yet another cell 
death subroutine.8 Despite of their diversity, these oncolytic peptide and peptide derivatives all 
appear to be able to stimulate anticancer immune responses, at least in specific circumstances. 
Thus, cancer cells treated with LTX-315 or LTX-401 in vitro can stimulate a protective 
antineoplastic immune response when injected into rodents.3, 7, 9-13 Moreover, LTX-315 treatments 
sensitize to subsequent immune checkpoint blockade with CTLA-4 antibodies,11 while tumors 
that are successfully cured with DTT-205 or DTT-304 established a long-term immune response 
rendering them resistant against later rechallenge with the cancer cells that had been eliminated 
from them.8 
 
Here, we compared the safety profiles of different lytic peptides to discover that LTX-401 (similar 
to LTX-315) was far less toxic than DTT-205 and DTT-304. We also investigated the capacity of 
LTX-401 to stimulate anticancer immune responses in three different experimental setups. Our 
results support the hypothesis that oncolysis by LTX-401 is highly immunogenic.   
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Results and Discussion  
 
Differential toxicity of oncolytic agents.  
In a retrospective study the safety profiles of oncolytic peptides and peptidomimetics at their 
therapeutically effective doses were compared. The onset of manifest discomfort or death that was 
defined as an endpoint for in vivo experimentation was evaluated for the sequential treatment of 
tumors established on C57Bl/6 mice with therapeutically effective doses of LTX-315, LTX-401, 
DTT-205 and DTT-304 (Fig. 1A). Data from in vivo experimentation utilizing oncolytic 
compounds in C57BL/6 mice bearing palpable subcutaneous solid tumors were evaluated by 
enumerating global survival (Fig. 1B). Whereas both experimental compounds DTT-205 and DTT-
304 led to death in a certain number of animals, LTX-401, similar to LTX-315, that is under clinical 
evaluation in patients with transdermally accessible tumors, did not depict any signs of adverse 
toxicity in vivo. 
 
Stimulation of anticancer immunity by LTX-401.  
To identify the capacity of LTX-401 to stimulate anticancer immune responses, we treated 
established MCA205 fibrosarcomas growing subcutaneously (s.c.) in C57BL/6 mice by daily 
intratumoral injection (up to 4 times) of the compound (or, as a control, its vehicle PBS) until 
macroscopically detectable tumors disappeared or persisted (Fig. 2A). This procedure greatly 
reduced tumor growth (Fig. 2B) and extended the longevity of the mice, yielding a survival rate of 
~22% at 60 days post-diagnosis (Fig. 2C). At this point, tumor-free mice were rechallenged by s.c. 
inoculation of the same tumor type (MCA205, injected into the opposite flank) or antigenically 
unrelated mammary carcinoma AT3 cells (injected into the same flank, though at a site distant from 
the primary MCA205 fibrosarcoma). Importantly, all mice that were cured by LTX-401 treatment 
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from their primary MCA205 tumor became resistant to rechallenge with MCA205 (but not AT3) 
cancer cells (Fig. 2D), supporting the idea that they had developed a long-term immunological 
memory. Very similar results were obtained when MCA205 fibrosarcomas were replaced by non-
small cell lung adenocarcinoma TC-1 cells (that have been engineered to express the human 
papilloma virus antigen E6). Again, local therapy with LTX-401 injections was able to greatly 
reduce the growth of primary TC-1 carcinomas (Fig. 2E), yielding a 60% survival rate at 60 days 
(Fig. 2F). Again, mice that were cured became resistant to rechallenge with TC-1 (but not 
MCA205) cells (Fig. 2G), confirming the contention that a tumor-specific memory immune 
response had been established.  
 
 
Limited abscopal effects of LTX-401-mediated tumor lysis.  
In the next step, we interrogated the experimental system for the induction of abscopal effects, i.e. 
a presumably immune-mediated long-distance effect of the injected LTX-401 peptide that would 
reduce the growth of a non-injected tumor. For this, we inoculated mice with MCA205 
fibrosarcomas into the right flank to create a primary tumor (that became palpable 8 days later) and 
shortly later (4 days after the first injection) a similar amount of MCA205 cells into the left flank 
to create a secondary tumor. Only the primary tumor was injected for up to 4 days until tumor 
disappearance with LTX-401 (or PBS as a vehicle control) and the growth of both the primary 
(treated) and secondary (untreated) tumors were monitored. The local treatment had a significant 
tumor growth reducing effect on primary tumors (Fig. 3A,B,D) yet only limited effects on 
secondary contralateral tumors (Fig. 3C,E). Hence, LTX-401-mediated oncolysis alone is not 
sufficient to induce a therapeutically relevant abscopal effect.  
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Combinatorial effects of LTX-401 and anti-CTLA4-mediated immune checkpoint blockade.  
Given the capacity of local LTX-401 therapy to induce memory immune responses and abscopal 
effects on distant lesions, we investigated the possibility that this agent would sensitize cancers to 
therapy with immune checkpoint blockers targeting CTLA-4 or PD-1. For this, established 
MCA205 fibrosarcomas were injected only once intratumorally and then subjected to 
immunotherapy with antibodies specific for CTLA-4, PD-1 or a combination of both (Fig. 4A). 
Continuous tumor monitoring led to the conclusion that the most efficient therapeutic regimen 
consisted in a combination of all three anticancer agents (LTX-401, CTLA-4 and PD-1). In 
contrast, single-agent therapies appeared to be relatively inefficient in this setting (Fig. 4B-F). 
When the survival of tumor-bearing animals was monitored, the combination of LTX-401 and dual 
checkpoint blockade (CTLA-4 plus PD-1) or the combination of LTX-401 and CTLA-4 (but 
not PD-1) alone were able to significantly extend life expectancy (Fig. 4G-H). Again, mice that 
had been rendered tumor-free for more than 50 days resisted rechallenge with the same cancer cell 
type from which they had been cured (MCA205), yet readily developed TC-1 cancers (Fig. 4I). 
Thus, as to be expected, mice that had been cured by a combination of local oncolysis and systemic 
immunotherapy had established a specific anticancer immune response. Sequential treatments of 
LTX-401 in combination with dual checkpoint blockade increased this effect and was able to 
achieve 100 % clearance of treated tumors (Fig. 5A,B,D). Of note in 6 out of 9 animals the 
combination of LTX-401 with dual checkpoint blockade not only cleared the treated tumor but also 




The results of this study suggest that LTX-401 can provide oncolysis with a relatively favorable 
safety profile when the agent is injected into established tumors. Indeed, LTX-401 could be injected 
daily on 4 subsequent days with zero fatalities. Oncolysis by LTX-401 yielded a rapid macroscopic 
response and allowed most of the tumors to become undetectable following several local injections. 
This procedure likely does not simply cause necrotic (and passive) lysis of neoplastic and stromal 
cells. Rather, it triggered some immunogenic events, be it the induction of immunogenic cell death 
or by the liberation of tumor-associated antigens from their tumor towards the draining lymph 
nodes.14 Irrespective of the exact molecular mechanisms accounting for these effects, there are at 
least three lines of evidence pleading in favor of LTX-401-triggered cancer-specific 
immunogenicity. First, animals that had been cured from their established cancers by LTX-401 
became resistance to rechallenge with the same cancer type. Second, one single intratumoral 
injection of LTX-401 (which turned out to be inefficient on its own in reducing tumor volume) 
sensitized the cancers to subsequent immunotherapy with antibodies blocking CTLA-4 or, more 
so, a combination of antibodies targeting CTLA-4 and PD-1. Third, in mice bearing two neoplastic 
lesions, one which was treated and another one that was left untreated, the combination of LTX-
401 with double immune checkpoint blockade did not only reduce the growth of the locally injected 
tumor but also mediated long-distance (abscopal) effects resulting in the control of most of the non-
injected cancers. 
 
Altogether, these results convincingly demonstrate that LTX-401 mediated oncolysis may 
advantageously combined with established immunotherapeutic regimens. 
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Materials & Methods 
 
Chemicals, cell culture media and supplements. All supplements and cell culture media were 
purchased from Thermo Fisher Scientific (Carlsbad, CA, US). LTX-401 was provided by Lytix 
Biopharma (Oslo, Norway). Cell culture support and consumables were obtained from Greiner 
Bio-One (Monroe, CA, US). Mouse fibrosarcoma cells MCA-205 and murine lung cancer TC-1 
cells were cultured in Glutamax®-containing DMEM medium supplemented with 10 % fetal bovine 
serum (FBS), and 10 mM HEPES. Cells were maintained in a humidified incubator at 37 °C with 
an atmosphere containing 5 % CO2. 
In vivo experimentation. Female wild-type C57BL/6 mice at the age of 6-8 weeks were obtained 
from Harlan France (Gannat, France) and kept under controlled conditions in the animal facility at 
the Gustave Roussy Campus Cancer in specific pathogen–free and temperature-controlled 
environment with 12 h day, 12 h night cycles and received food and water ad libitum. Animal 
experiments were conducted in compliance with the EU Directive 63/2010 and protocols 
2013_094A and were approved by the Ethical Committee of the Gustave Roussy Campus Cancer 
(CEEA IRCIV/IGR no. 26, registered at the French Ministry of Research). MCA205 or TC-1 
tumors were established in C57BL/6 hosts by subcutaneously inoculating 5 x 105 cells. When 
tumors became palpable, either 0.25 mg (for each injection of sequential treatment) or 0.4 mg (for 
single injection) of LTX-401 was injected intratumorally. Remaining tumor tissue was treated on 
subsequent days accordingly and animal well-being and tumor growth were monitored. Mice were 
sacrificed when tumor size reached end-point or signs of obvious discomfort associated to the 
treatment were observed always following the EU Directive 63/2010 and our Ethical Committee 
advice. Surviving and tumor-free animals were analyzed and kept for more than 30 days before 
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subcutaneous rechallenge with 5 x 105 live TC-1 in one flank and 5 x 105 live MCA205 cells 
injected in the contralateral flank. In case of previously-injected TC-1 tumor-free animals the 
location of the injected cells was inverted. Animals were monitored and tumor growth documented 
regularly until end-points were reached or signs of obvious discomfort were observed. Statistical 
analysis was performed employing 2-way ANOVA analysis followed by Bonferroni’s test 
comparing to control conditions (* p < 0.05, ** p < 0.01 and ***p < 0.001). Abscopal effects were 
analyzed by inoculating C57BL/6 hosts subcutaneously with 5 x 105 MCA205 or TC-1 cells. 4 
days later the same number of cells was inoculated on the contralateral side to establish a second 
syngeneic tumor. Following exclusively primary tumors were treated with the oncolytic LTX-401 
as described above and tumor sizes of both primary and secondary tumor were monitored and 
documented regularly until end-points were reached or signs of obvious discomfort were observed. 
Retrospective study. The adverse toxicity of sequential intratumoral injections of oncolytic 
peptides and peptidomimetics at their respective therapeutically effective dose such as LTX-315 
(0.3 mg/injection), LTX-401 (0.25 mg/injection), DTT-205 and DTT-304 (both at 1.5 
mg/injection) was evaluated. Data from in vivo experimentation utilizing oncolytic compounds in 
C57BL/6 mice bearing palpable subcutaneous solid tumors were collected from these two studies, 
11 and 8 and unpublished data. Animals that depicted adverse toxic effects were enumerated and 
the percentage of mice that depicted an onset of discomfort upon treatment was plotted.  
Immune checkpoint blockade. Immune checkpoint blockade was mounted by sequential 
intraperitoneal injections of 200 µg monoclonal antibodies targeting PD-1 (Clone 29F.1A12, 
BioXcell, West Lebanon, NH, USA) or CTLA-4 (Clone 9D9, BioXcell) alone or in combination 
at day 6, 9 and 12 post treatment. Animals were monitored and tumor growth documented regularly 
until end-points were reached or signs of obvious discomfort were observed. Statistical analysis 
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was performed employing 2-way ANOVA analysis followed by Bonferroni’s test comparing to 
control conditions (* p < 0.05, ** p < 0.01 and ***p < 0.001).  
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Figure 1. Absence of adverse toxicity in LTX-401-treated mice. In a retrospective study the 
adverse toxicity of sequential intratumoral injections of oncolytic peptides and peptidomimetics at 
their respective therapeutically effective dose such as LTX-315 (0.3 mg/injection), LTX-401 (0.25 
mg/injection), DTT-205 and DTT-304 (both at 1.5 mg/injection) was evaluated. Note that these 
doses have been optimized to obtain an optimal antitumor effect. Data from in vivo 
experimentation utilizing oncolytic compounds in C57BL/6 mice bearing palpable subcutaneous 
solid tumors were evaluated and global survival was enumerated (A). The percentage of animals 
that survived without severe discomfort requiring their euthanasia is indicated (B).  
 
Figure 2. In vivo activity of LTX-401 on subcutaneous MCA205 fibrosarcoma in 
immunocompetent animals. Mouse fibrosarcoma MCA205 cells were injected subcutaneously in 
syngeneic C57BL/6 mice and palpable tumors arising thereof were treated with sequential 
intratumoral injections of 0.25 mg LTX-401 as indicated in (A). LTX-401 induced efficient 
oncolysis an effect that is reflected in reduced tumor growth (B), and increased overall survival (C) 
(Chi2 test, **p<0.01, n=12). Rechallenge of animals cured from MCA205 fibrosarcoma with 
MCA205 several weeks after the initial therapy on the contralateral flank and challenged with 
syngeneic mouse AT3 breast cancer cells on the ipsilateral side resulted in efficient rejection of 
MCA205 but aggressive tumor growth of AT3 (D). Thus LTX-401 caused the generation of 
immunological memory that sufficed in rejecting isogenic tumors. Similar effects were obtained 
when mouse lung cancer TC-1 cells were inoculated subcutaneously in syngeneic C57BL/6 mice 
and tumors and were treated when palpable with repeated injections of 0.25 mg LTX-401 
intratumorally as shown in (A). LTX-401 induced efficient oncolysis and tumor control in some 
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animals reflected in reduced tumor growth and cure of some animals (E), and increased overall 
survival (F) (Chi2 test, ***p<0.001). Animals cured from subcutaneous TC-1 lung cancers were 
rechallenged with TC-1 several weeks after the initial therapy on the contralateral and challenged 
with syngeneic mouse MCA205 fibrosarcoma cells on the ipsilateral side. This maneuver resulted 
in efficient rejection of TC-1 but aggressive tumor growth of MCA205 (G). Thus, also in this 
model system LTX-401 caused the generation of immunological memory in cured animals that 
sufficed in rejecting isogenic tumors. 
 
Figure 3. LTX-401 treatment of subcutaneous MCA205 fibrosarcoma induces limited 
abscopal effects. C57BL/6 mice were inoculated with murine fibrosarcoma MCA205 
subcutaneously on one side and four days later on the contralateral flank. Palpable primary tumors 
arising from the first injection were treated with sequential intratumoral injections of 0.25 mg LTX-
401 as indicated in (A). LTX-401 induced efficient oncolysis in primary tumors which is reflected 
in reduced tumor growth and tumor clearance in some animals (B). In parallel tumors arising from 
untreated secondary lesions were monitored and abscopal effects were documented as tumor 
growth in separate curves (C). Lung cancer TC-1 cells were injected subcutaneously into C57BL/6 
mice on one flank and four days later on the contralateral side. Palpable primary tumors arising 
from the first injection were treated with sequential injections of 0.25 mg LTX-401 intratumorally 
as indicated in (A). LTX-401 induced efficient oncolysis in primary tumors which is reflected in 
reduced tumor growth and tumor clearance in some animals (D). In parallel tumors arising from 
untreated secondary lesions were monitored and abscopal effects were documented as tumor 
growth curves (E). 
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Figure 4: Combination of single LTX-401 treatment with immune checkpoint blockade 
increases its efficacy. C57BL/6 mice subcutaneously implanted with MCA205 fibrosarcoma were 
injected intratumorally when tumors became palpable with a single injection of 0.25 mg LTX-401 
as indicated in (A). Immune checkpoint blockade was mounted by sequential injections of 
monoclonal antibodies targeting CTLA-4 or PD-1 alone or in combination at day 6, 9 and 12 post 
treatment. LTX-401 induced efficient oncolysis which is reflected in reduced tumor growth and 
tumor clearance in some animals. This effect was increased in combination with CTLA-4 and PD-
1 cotreatment as depicted in separate tumor growth curves (B-E) and overall survival plots (Chi2 
test, **p<0.01) (F-H). Rechallenge of animals cured from MCA205 fibrosarcoma with MCA205 
several weeks after the initial therapy on the contralateral and challenged with syngeneic mouse 
TC-1 lung cancer cells on the ipsilateral side resulted in efficient rejection of MCA205 but 
aggressive tumor growth of TC-1 (I). Thus LTX-401 caused the generation of immunological 
memory that led to the rejection of isogenic tumors. 
 
Figure 5: Sequential LTX-401 treatment with double immune checkpoint blockade exhibits 
systemic antitumor immunity C57BL/6 mice were inoculated with murine fibrosarcoma 
MCA205 subcutaneously on one side and four days later on the contralateral flank. Palpable 
primary tumors arising from the first injection were treated with sequential injections of 0.25 mg 
LTX-401 as indicated in (A). Immune checkpoint blockade was mounted by sequential injections 
of double immune checkpoint blockade with monoclonal antibodies targeting CTLA-4 or PD-1 at 
day 6, 9 and 12 post treatment. Immune checkpoint inhibition alone did not control tumor growth 
of LTX-401-treated primary (B) and distant (C) tumors. In contrast, combination of sequential 
LTX-401 treatment with double immune checkpoint blockade cleared 100 % of LTX-401-treated 
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